

# Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma

**Running Title:** Expanded access to COVID-19 convalescent plasma

Jonathon W. Senefeld<sup>1†</sup>, Ph.D., Patrick W. Johnson<sup>2†</sup>, B.S., Katie L. Kunze<sup>3†</sup>, Ph.D., Noud van Helmond<sup>4†</sup>, M.D., Stephen A. Klassen<sup>1</sup>, Ph.D., Chad C. Wiggins<sup>1</sup>, Ph.D., Katelyn A. Bruno<sup>5</sup>, Ph.D., Michael A. Golafshar<sup>3</sup>, M.S., Molly M. Petersen<sup>3</sup>, B.S., Matthew R. Buras<sup>3</sup>, M.S., Allan M. Klompas<sup>1</sup>, M.B., B.Ch., B.A.O., Matthew A. Sexton<sup>1</sup>, M.D., Juan C. Diaz Soto<sup>1</sup>, M.D., Sarah E. Baker<sup>1</sup>, Ph.D., John R.A. Shepherd<sup>1</sup>, M.D., Nicole C. Verdun<sup>6</sup>, M.D., Peter Marks<sup>6</sup>, M.D., Ph.D., Camille M. van Buskirk<sup>7</sup>, M.D., Jeffrey L. Winters<sup>7</sup>, M.D., James R. Stubbs<sup>7</sup>, M.D., Robert F. Rea<sup>8</sup>, M.D., Vitaly Hrasevich<sup>1</sup>, M.D., Ph.D., Emily R. Whelan<sup>5</sup>, B.S., Andrew J. Clayburn<sup>1</sup>, B.S., Kathryn F. Larson<sup>8</sup>, M.D., Juan G. Ripoll<sup>1</sup>, M.D., Kylie J. Andersen<sup>1</sup>, B.S., Matthew N.P. Vogt<sup>1</sup>, M.D., Joshua J. Dennis<sup>1</sup>, B.S., Riley J. Regimbal<sup>1</sup>, B.S., Philippe R. Bauer<sup>9</sup>, M.D., Ph.D., Janis E. Blair<sup>10</sup>, M.D., Katherine Wright<sup>11</sup>, BA, Joel T. Greenshields<sup>12</sup>, MS, Nigel S. Paneth<sup>13†</sup>, M.D., M.P.H., DeLisa Fairweather<sup>5†</sup>, Ph.D., R. Scott Wright<sup>8,14†</sup>, M.D., Arturo Casadevall<sup>15†</sup>, M.D., Ph.D., Rickey E. Carter<sup>2†</sup>, Ph.D., Michael J. Joyner<sup>1†\*</sup>, M.D.

## AFFILIATIONS

<sup>1</sup>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, United States of America

<sup>2</sup>Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida, United States of America

<sup>3</sup>Department of Health Sciences Research, Mayo Clinic, Scottsdale, Arizona, United States of America

<sup>4</sup>Department of Anesthesiology, Cooper Medical School of Rowan University, Cooper University Health Care, Camden, New Jersey, United States of America

<sup>5</sup>Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, United States of America

<sup>6</sup>Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America

<sup>7</sup>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America

<sup>8</sup>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, United States of America

<sup>9</sup>Department of Internal Medicine, Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, Minnesota, United States of America

<sup>10</sup>Department of Internal Medicine, Division of Infectious Diseases, Mayo Clinic, Phoenix, Arizona, United States of America

<sup>11</sup>School of Sustainability, Arizona State University, Tempe, Arizona, United States of America

<sup>12</sup>Department of Kinesiology, Indiana University, Bloomington, Indiana, United States of America

<sup>13</sup>Departments of Epidemiology and Biostatistics and Pediatrics and Human Development, College of Human Medicine, Michigan State University, East Lansing, Michigan, United States of America

<sup>14</sup>Department of Human Research Protection Program, Mayo Clinic, Rochester, Minnesota, United States of America

<sup>15</sup>Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America

†These authors have contributed equally to this work.

## Abstract

### Background

The United States (US) Expanded Access Program (EAP) to COVID-19 convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID-19). While randomized clinical trials were in various stages of development and enrollment, there was an urgent need for widespread access to potential therapeutic agents particularly for vulnerable racial and ethnic minority populations who were disproportionately affected by the pandemic. The objective of this study is to report on the demographic, geographic, and chronological access to COVID-19 convalescent plasma in the US via the EAP.

### Methods and findings

Mayo Clinic served as the central IRB for all participating facilities and any US physician could participate as local physician–principal investigator. Registration occurred through the EAP central website. Blood banks rapidly developed logistics to provide convalescent plasma to hospitalized patients with COVID-19. Demographic and clinical characteristics of all enrolled patients in the EAP were summarized. Temporal trends in access to COVID-19 convalescent plasma were investigated by comparing daily and weekly changes in EAP enrollment in response to changes in infection rate on a state level. Geographical analyses on access to convalescent plasma included assessing EAP enrollment in all national hospital referral regions as well as assessing enrollment in metropolitan and less populated areas which did not have access to COVID-19 clinical trials.

24 From April 3 to August 23, 2020, 105,717 hospitalized patients with severe or life-  
25 threatening COVID-19 were enrolled in the EAP. A majority of patients were older than  
26 60 years of age (57.8%), male (58.4%), and overweight or obese (83.8%). There was  
27 substantial inclusion of minorities and underserved populations, including 46.4% of  
28 patients with a race other than White, and 37.2% of patients were of Hispanic ethnicity.  
29 Severe or life-threatening COVID-19 was present in 61.8% of patients and 18.9% of  
30 patients were mechanically ventilated at time of convalescent plasma infusion.  
31 Chronologically and geographically, increases in enrollment in the EAP closely followed  
32 confirmed infections across all 50 states. Nearly all national hospital referral regions  
33 enrolled patients in the EAP, including both in metropolitan and less populated areas.

#### 34 **Conclusions**

35 The EAP successfully provided widespread access to COVID-19 convalescent plasma in  
36 all 50 states, including for underserved racial and ethnic minority populations. The  
37 efficient study design of the EAP may serve as an example framework for future efforts  
38 when broad access to a treatment is needed in response to a dynamic disease affecting  
39 demographic groups and areas historically underrepresented in clinical studies.

## 40 **Introduction**

41 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of  
42 the coronavirus disease 2019 (COVID-19), spread rapidly across the United States (US)  
43 after confirmation of the first case of COVID-19 in the US in December 2019 and January  
44 2020 [1]. By March of 2020 in the Northeast region of the US, community transmission  
45 was occurring in major metropolitan areas and hospitals became overwhelmed with  
46 admissions for severe or life-threatening COVID-19 [1]. Although most infected persons  
47 have few or no symptoms despite high SARS-CoV-2 viral loads [2], a smaller group of  
48 persons develop hypoxemia and severe COVID-19 leading to hospitalization with  
49 supplemental oxygen support [3]. Severe cases of COVID-19 can lead to respiratory  
50 failure, which is among the leading causes of death in persons with COVID-19 [4].

51 The cornerstone of treatment for patients with COVID-19 was symptomatic and  
52 supportive management [5]. Because there was a dearth of evidence supporting the  
53 efficacy of COVID-19 therapeutic strategies during the early stages of this public health  
54 emergency, immunomodulatory agents and antivirals, represented promising strategies  
55 that were anticipated to provide benefit to patients with COVID-19 [6, 7]. Passive  
56 immunotherapy using convalescent plasma or serum had been used previously to treat  
57 acute respiratory tract infections [8-10], including severe acute respiratory syndrome  
58 coronavirus 1 infection (SARS-CoV-1) [11], and early studies suggested potential efficacy  
59 of convalescent plasma in the treatment of COVID-19 [12-14].

60 In late March and early April of 2020, COVID-19 convalescent plasma began to be  
61 administered to patients under single-patient emergency investigational new drug (eIND)

62 applications while randomized clinical trials of COVID-19 convalescent plasma were in  
63 various stages of development and enrollment. For example, one institution in New York  
64 City had 45 eIND applications submitted to and approved by the US Food and Drug  
65 Administration (FDA) in a two-week period in late March 2020 [15]. The single-patient  
66 eIND application process requires substantial administrative support from local  
67 institutions and the US FDA and limits widespread and high-volume access to  
68 convalescent plasma, particularly for underserved and racial and ethnic minority  
69 populations, who were disproportionately affected by the COVID-19 pandemic [16, 17].  
70 Additionally, clinical trials often have inclusion criteria that are restricted to a specific  
71 geographical region or disease status (e.g. hospitalized, but not severe patients) and  
72 have exclusion criteria (e.g. prisoners or recipients of solid organ transplant). Thus,  
73 inherently, more traditional regulatory pathways for obtaining access to COVID-19  
74 convalescent plasma (eIND or clinical trials) result in limited access to convalescent  
75 plasma and may potentially limit the ability to comprehensively study the safety of  
76 convalescent plasma for the treatment of COVID-19.

77 To provide access to a COVID-19 treatment and provide a framework for standardized  
78 safety data collection, Mayo Clinic initiated the Expanded Access Program (EAP) for  
79 COVID-19 convalescent plasma. The primary objective of the EAP was to provide access  
80 to convalescent plasma for hospitalized patients in the US with severe or life-threatening  
81 COVID-19 [18]. The EAP started as a national registry approved to enroll 5,000 patients,  
82 but due to a national demand for COVID-19 plasma, enrollment goals were extended in  
83 collaboration with the US Food and Drug Administration (FDA) and the Biomedical  
84 Advanced Research and Development Authority (BARDA) with the aim for the EAP to

85 become a broad national program obviating the need for individual patient INDs. We  
86 herein assess the extent to which the EAP was successful in terms of providing access  
87 to COVID-19 convalescent plasma by presenting demographic, geographic, and  
88 chronological characteristics of enrollment in the EAP alongside publicly available data of  
89 state-level trends in COVID-19.

## 90 **Methods**

91 As described previously [19-21], the EAP was a national registry for hospitalized patients  
92 with COVID-19. Collaborative support was provided by the US BARDA and FDA; funding  
93 to support the study infrastructure and study-related costs at participating sites was  
94 provided under contract from BARDA. Mayo Clinic served as the academic research  
95 organization coordinating the national registry. The Mayo Clinic Institutional Review  
96 Board (IRB), the central IRB for the registry, approved the protocol (IRB #20-0033412,  
97 NCT#: NCT04338360), all amendments, and provided regulatory oversight for all sites  
98 and investigators. The principal investigator (M.J.J.) was the regulatory sponsor. A Data  
99 and Safety Monitoring Board oversaw the safety analyses and advised the regulatory  
100 sponsor and the Mayo Clinic IRB on risk.

## 101 **Patients**

102 Patients were eligible for enrollment in the EAP if they were: aged 18 years or older,  
103 hospitalized with a laboratory confirmed diagnosis of or suspected/probable infection with  
104 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and either had or were  
105 judged by a healthcare provider to be at high risk of progression to severe or life-  
106 threatening COVID-19. Severe COVID-19 was defined by one or more of the following:

107 dyspnea, respiratory frequency  $\geq 30/\text{min}$ , blood oxygen saturation  $\leq 93\%$ , partial pressure  
108 of arterial oxygen to fraction of inspired oxygen ratio  $< 300$ , lung infiltrates  $> 50\%$  within  
109 24 to 48 hours of hospital admission. Life-threatening COVID-19 was defined as one or  
110 more of the following: respiratory failure, septic shock, and multiple organ dysfunction or  
111 failure. To maximize access to COVID-19 convalescent plasma, no exclusion criteria  
112 were used, thereby, enabling access to vulnerable adult populations who may not be  
113 eligible for clinical trials, including pregnant women and prisoners.

## 114 **Enrollment**

115 All hospitals and acute care facilities in the US and its territories, and any physician  
116 licensed in the US, were allowed to register for participation provided they agreed to  
117 adhere to the online available treatment protocol [18], as well as US FDA and state  
118 regulations. All patient registration was facilitated through the central study website [22].  
119 A single consent form, available in eight languages, was used by all participating sites.  
120 Informed consent was obtained from the patient or a legally authorized representative  
121 prior to enrollment, except for patients in whom an emergency consent was utilized.  
122 Criteria for emergency consent were consistent with the federal regulation governing  
123 emergency consent [23]. COVID-19 convalescent plasma transfusate and convalescent  
124 plasma donors details have been described elsewhere [19-21].

## 125 **Study data**

126 Demographic and clinical characteristics of enrolled patients were collected using the  
127 Research Electronic Data Capture system (REDCap, v.9.1.15 – v10.0.33 Vanderbilt  
128 University, Nashville, TN) [24, 25]. REDCap is US Health Insurance Portability and

129 Accountability Act (HIPAA) compliant and the US FDA authorized its use in the EAP [20,  
130 21]. The EAP was expeditiously established and implemented to provide access to a  
131 potential therapeutic for COVID-19 at a time when no satisfactory therapies for COVID-  
132 19 were available. To maximize access in the context of stress on clinical staff at  
133 participating sites during the COVID-19 pandemic, the online case reporting forms were  
134 designed to optimize convenience. Race (American Indian or Alaska Native, Asian, Black  
135 or African American, Native Hawaiian or Other Pacific Islander, White) and ethnicity  
136 (Hispanic or Latino, Not Hispanic or Latino) were reported into categories by site  
137 personnel consistent with guidelines provided by the US Office of Management and  
138 Budget [26].

139 The database was updated as needed to fulfill the requirements of the EAP IRB and data  
140 collection requirements of BARDA. As the original goal of data collection was to determine  
141 safety, updates were needed to capture additional data as enrollment expanded and the  
142 study progressed. Enrollment into the EAP was stopped after the FDA issued an  
143 emergency use authorization (EUA) for COVID-19 convalescent plasma on August 23rd,  
144 2020. Data clarification requests were sent to participating investigators as needed until  
145 the database was locked to further data changes on December 16th, 2020. The study  
146 protocol, case report forms with completion instructions, and informed consent form are  
147 publicly available on the study website [22], archived by the US Library of Congress.

#### 148 **COVID-19 epidemiological data sources**

149 In order to contextualize whether the patients enrolled in the EAP were reflective of the  
150 US population, race and ethnicity data of each state and US territories were retrieved



151 from the US Census Bureau [27], using the same race and ethnic categories that were  
152 collected in the EAP. COVID-19-confirmed infection rates per day for each US state were  
153 obtained from the New York Times database [28]. Hospital referral regions are regional  
154 healthcare markets defined by where the majority of residents within that region have  
155 their hospitalization stays. The 306 hospital referral regions in the US were retrieved from  
156 the Dartmouth Atlas of Health Care. Metropolitan and less populated US region data were  
157 obtained from US Census Bureau data [27] and the 2010 Office of Management and  
158 Budget Standards that define metropolitan and micropolitan areas based on statistical  
159 assessments [29]. Micropolitan areas were defined as areas with a population of at least  
160 10,000 and less than 50,000 residents. The US regions of Northeast, Southeast, Midwest,  
161 Southwest, and West were delineated using commonly used regions [30]. Characteristics  
162 of US hospitals were retrieved from American Hospital Directory [31] and the Centers for  
163 Medicare and Medicaid [32]. The potential limitations of the data sources are described  
164 in the discussion.

## 165 **Statistical Considerations**

166 To provide a comprehensive report of the enrollment data on the EAP program descriptive  
167 statistics are presented for demographic and clinical variables of interest. To examine  
168 enrollment in the EAP over time, dot plots were used to show the number of enrollments,  
169 for each US state individually and aggregated by region by day of the study. Additionally,  
170 EAP enrollment was compared to the number of confirmed COVID-19 cases per state  
171 over the duration of the study. During the window of EAP enrollment, a moving 7-day  
172 average was calculated for daily enrollments and COVID-19 cases within each state that  
173 enrolled more than 10 patients in total in the EAP. To compare and visualize relative

174 patterns, these averages were scaled between 0 (lowest cases/enrollments) and 1 (peak  
175 cases/enrollments) and overlaid on a geo-faceted graph. The geo-faceted graph contains  
176 one cell for each US state and is placed at approximately the same location on the graph  
177 as the corresponding geographical location. Differences in geographic access to  
178 convalescent plasma through the EAP were assessed by examining enrollment across  
179 micropolitan and metropolitan areas and the number of hospitals enrolling patients in  
180 each hospital referral region in the United States. All data were processed using R version  
181 3.6.2.

## 182 **Results**

### 183 **Patient Characteristics**

184 From April 3rd to August 23rd, 2020, 105,717 hospitalized patients with severe or life-  
185 threatening COVID-19 were enrolled in the EAP and ~95,000 patients were transfused  
186 with COVID-19 convalescent plasma. The EAP halted enrollment forthwith after the US  
187 FDA issued an emergency use authorization (EUA) for COVID-19 convalescent plasma,  
188 citing that the totality of scientific evidence indicated that convalescent plasma was safe  
189 [20, 21] and a potentially promising therapeutic treatment on August 23, 2020 [33]. This  
190 authorization enabled physicians to use COVID-19 convalescent plasma without  
191 requesting IND permission and obviated the need for access to convalescent plasma via  
192 the EAP.

193 Enrolled patients' demographic characteristics including age, gender, race, ethnicity, and  
194 other clinical variables at time of transfusion are shown in **Table 1**. A majority of patients  
195 were older than 60 years of age (57.8%), male (58.4%), overweight or obese (83.8%),

196 and had never smoked (69.7%). There was substantial inclusion of minorities and  
197 underserved populations, including 46.4% of patients with a race other than White, and  
198 37.2% of patients were of Hispanic ethnicity. Pre-existing conditions present among  
199 enrolled patients are displayed in **Supplemental Table 1**. Of those patients enrolled,  
200 61.8% had severe or life-threatening COVID-19, 42.3% were in the ICU, and 18.9%  
201 received mechanical ventilation at time of transfusion. A small proportion of patients  
202 (3.9%) had no form of hospital respiratory support prior to infusion. A large percentage of  
203 patients had severe risk factors of dyspnea (75.7%), oxygen saturation  $\leq$  93% (75.0%),  
204 and acute respiratory failure (60.6%). Patients were also prescribed steroids (65.7%),  
205 azithromycin (49.0%) and remdesivir (37.6%) during their hospital stay. The median  
206 number of days between diagnosis of COVID-19 and the first transfusion was 4 days  
207 (interquartile range, 2 – 8 days), and nearly half of transfused patients (45.0%) received  
208 convalescent plasma within 3 days of COVID-19 diagnosis, which often occurred during  
209 hospital admission.

210 **Table 1.** Characteristics of Patients with COVID-19 who enrolled in the US Expanded  
211 Access Program to convalescent plasma.

<b>Baseline Data</b>	
	<i>number/total number (percent)</i>
<b>Age at Enrollment (years)</b>	
18 to 39	9,630/105,717 (9.1)
40 to 59	34,968/105,717 (33.1)
60 to 69	26,305/105,717 (24.9)
70 to 79	21,585/105,717 (20.4)
80 or older	13,229/105,717 (12.5)
<b>Gender</b>	
Female	43,544/105,717 (41.2)
Male	61,761/105,717 (58.4)
Intersex	157/105,717 (0.1)
Transgender	144/105,717 (0.1)
Prefer not to disclose	111/105,717 (0.1)

<b>Baseline Data</b>	
	<i>number/total number (percent)</i>
<b>Weight Status</b>	
Underweight	1,528/104,046 (1.5)
Normal Weight	15,313/104,046 (14.7)
Overweight	28,524/104,046 (27.4)
Obese	58,681/104,046 (56.4)
<b>Race</b>	
American Indian and Alaska Native alone	1,434/105,715 (1.4)
Asian alone	3,432/105,715 (3.2)
Black alone	19,225/105,715 (18.2)
Native Hawaiian and Other Pacific Islander alone	605/105,715 (0.6)
White alone	56,687/105,715 (53.6)
Other or Unknown	23,849/105,715 (22.6)
Two or more races	483/105,715 (0.5)
<b>Ethnicity</b>	
Hispanic/Latino	39,335/105,717 (37.2)
Not Hispanic/Latino	66,382/105,717 (62.8)
<b>Enrollment Month</b>	
April	8,719/105,717 (8.2)
May	15,873/105,717 (15.0)
June	17,965/105,717 (17.0)
July	39,321/105,717 (37.2)
August	23,839/105,717 (22.5)
<b>Smoking Status</b>	
Current smoker	1,690/32,831 (5.1)
Past smoker	8,250/32,831 (25.1)
Never smoked	22,891/32,831 (69.7)
<b>Transfusion Status</b>	
Transfused	94,788/105,717 (89.7)
Plasma Not Ordered/Given	8,177/105,717 (7.7)
Unreported	2,752/105,717 (2.6)
<b>Current severe or life-threatening COVID-19</b>	65,336/105,717 (61.8)
<b>Highest level of hospital respiratory support prior to transfusion</b>	
None	3,619/93,776 (3.9)
Oxygen supplementation	35,137/93,776 (37.5)
Non-Invasive Positive-Pressure Ventilation NIPPV	36,454/93,776 (38.9)
Mechanical ventilation/intubation	18,273/93,776 (19.5)
Extra Corporeal Membrane Oxygenation (ECMO)	293/93,776 (0.3)
<b>Intensive Care Unit (ICU) care prior to infusion</b>	39,929/94,383 (42.3)
<b>Mechanical Ventilation prior to infusion</b>	17,864/94,328 (18.9)
<b>Severe Risk Factors</b>	
Dyspnea	49,486/65,336 (75.7)
Respiratory frequency $\geq$ 30/min	25,520/65,336 (39.1)
Blood oxygen saturation $\leq$ 93%	48,979/65,336 (75.0)

<b>Baseline Data</b>	
	<i>number/total number (percent)</i>
PaO <sub>2</sub> :FiO <sub>2</sub> ratio < 300	16,541/65,336 (25.3)
Lung infiltrates > 50% within 24 to 48 hours	24,389/65,336 (37.3)
Respiratory failure	39,617/65,336 (60.6)
Septic shock	4,622/65,336 (7.1)
Multiple organ dysfunction or failure	5,831/65,336 (8.9)
<b>Medications during hospital stay</b>	
ARB	2,942/43,805 (6.7)
Ace Inhibitor	3,752/43,805 (8.6)
Azithromycin	21,470/43,805 (49.0)
Remdesivir	16,460/43,805 (37.6)
Steroids	28,764/43,805 (65.7)
Chloroquine	84/43,805 (0.2)
Hydroxychloroquine	7,802/43,805 (17.8)
<b>Census Region</b>	
Midwest	14,896/105,717 (14.1)
Northeast	11,557/105,717 (10.9)
South	58,285/105,717 (55.1)
West	20,748/105,717 (19.6)
Other	231/105,717 (0.2)
<b>Micro/Metropolitan</b>	
Metropolitan	100,633/105,717 (95.2)
Micropolitan	4,412/105,717 (4.2)
None	672/105,717 (0.6)
<b>Rural Referral Center</b>	
	16,566/104,534 (15.8)
<b>Sole Community Hospital</b>	
	4,520/104,534 (4.3)
<b>Part of a Health System</b>	
	89,234/104,534 (85.4)
<b>Major Teaching Hospital (member of COH)</b>	
	26,012/101,511 (25.6)
<b>University Affiliated</b>	
	56,689/104,534 (54.2)

## 212 Geospatial Trends in Enrollment


213 Patients were enrolled from each state in the US, the District of Columbia, and the US  
 214 territories of Puerto Rico, and the US Virgin Islands (**Table 2**). A large percentage of  
 215 patients were enrolled in the Southern region of the US (55.1%) and most patients  
 216 enrolled in a hospital within a metropolitan area (95.2%) that was part of a health system  
 217 (85.4%) and/or was university affiliated (54.2%).

218 **Table 2.** Tabular summaries of patient enrollment in the US Expanded Access Program  
 219 (EAP) to convalescent plasma and US COVID-19 cases during the EAP enrollment  
 220 period, stratified by US state or territory in alphabetical order.

State	EAP Summaries			Population and COVID+ Ratios		
	Enrolling Sites	Enrolled Patients	Transfused Patients	COVID+ Cases / Enrollment	Enrollments / 10,000 people	Enrollments / 1,000 COVID+ Cases
Alabama	35	2,408	2,016	51.9	4.9	19.3
Alaska	3	59	58	100.5	0.8	9.9
Arizona	41	3,961	3,680	50.6	5.4	19.8
Arkansas	16	597	498	101.5	2.0	9.9
California	236	11,874	10,076	59.2	3.0	16.9
Colorado	27	646	628	84.3	1.1	11.9
Connecticut	23	1,022	928	48.3	2.9	20.7
Delaware	4	372	366	45.9	3.8	21.8
District of Columbia	9	349	278	38.4	4.9	26.0
Florida	158	12,553	11,206	49.0	5.8	20.4
Georgia	74	5,424	4,921	46.0	5.1	21.7
Hawaii	8	320	316	25.6	2.3	39.1
Idaho	10	156	131	202.5	0.9	4.9
Illinois	92	3,137	2,709	73.5	2.5	13.6
Indiana	64	1,746	1,610	53.7	2.6	18.6
Iowa	35	1,299	1,222	49.8	4.1	20.1
Kansas	23	703	609	61.0	2.4	16.4
Kentucky	40	884	836	56.8	2.0	17.6
Louisiana	44	1,548	1,351	92.0	3.3	10.9
Maine	9	62	58	67.5	0.5	14.8
Maryland	42	1,812	1,592	58.9	3.0	17.0
Massachusetts	37	907	790	133.2	1.3	7.5
Michigan	61	1,071	875	97.0	1.1	10.3
Minnesota	35	1,052	1,008	71.5	1.9	14.0
Mississippi	19	1,380	1,313	59.3	4.6	16.9
Missouri	41	1,347	1,262	62.9	2.2	15.9
Montana	8	133	127	54.3	1.2	18.4
Nebraska	18	509	471	66.9	2.6	15.0
Nevada	19	1,303	1,128	52.2	4.2	19.2
New Hampshire	8	127	92	54.0	0.9	18.5
New Jersey	66	2,768	2,452	62.0	3.1	16.1
New Mexico	14	433	415	57.7	2.1	17.3
New York	110	4,492	4,146	79.1	2.3	12.6
North Carolina	56	1,769	1,627	94.1	1.7	10.6
North Dakota	7	226	216	51.7	3.0	19.4
Ohio	77	2,184	2,007	55.2	1.9	18.1
Oklahoma	27	1,415	1,324	41.0	3.6	24.4
Oregon	17	320	290	81.2	0.8	12.3


State	EAP Summaries			Population and COVID+ Ratios		
	Enrolling Sites	Enrolled Patients	Transfused Patients	COVID+ Cases / Enrollment	Enrollments / 10,000 people	Enrollments / 1,000 COVID+ Cases
Pennsylvania	90	1,930	1,702	68.9	1.5	14.5
Puerto Rico	31	222	184	148.3	0.7	6.7
Rhode Island	9	248	242	86.2	2.3	11.6
South Carolina	38	3,970	3,530	29.6	7.7	33.7
South Dakota	6	427	409	31.3	4.8	31.9
Tennessee	51	2,592	2,444	57.6	3.8	17.4
Texas	221	19,363	17,507	32.8	6.7	30.4
Virgin Islands	2	9	6	123.2		8.1
Utah	8	592	573	86.4	1.8	11.6
Vermont	1	1	1	1,303.0	0.0	0.8
Virginia	51	1,747	1,480	68.2	2.0	14.7
Washington	34	942	881	76.6	1.2	13.1
West Virginia	11	102	88	98.6	0.6	10.1
Wisconsin	62	1,195	1,100	66.3	2.1	15.1
Wyoming	4	9	9	411.6	0.2	2.4

221 Patients were enrolled by 12,879 healthcare providers from 2,722 hospitals and acute  
222 care facilities across the US, **Figure 1**. COVID-19 convalescent plasma was provided by  
223 317 blood banks. The median number of participants per site was 22 (range, 1 to 1,175).  
224 While 2,722 sites were registered, 490 (18.0%) enrolled no patients, 732 (26.9%) enrolled  
225 between 1 and 10 patients, and 1,500 (55.1%) enrolled more than 10 patients. Registered  
226 sites encompassed nearly all hospital referral regions in the US, **Figure 2**. Sites  
227 participation occurred both in metropolitan and non-metropolitan areas and from different  
228 hospital types ranging from community hospitals to major teaching hospitals, **Table 1 and**  
229 **Supplemental Table 2**.




239





251 Recognizing the disproportionate effects of the COVID-19 pandemic on minority  
252 communities [17], the EAP sought widespread access to convalescent plasma including  
253 in all representations populations. Patient enrollment stratified by race and ethnicity  
254 groups is displayed in **Figure 3**, relative to 100,000 people from US census.




255

256 **Figure 3. Patient enrollment in the US Expanded Access Program (EAP) stratified**  
257 **by race and ethnic group, relative to 100,000 people from US census per age, race**  
258 **and ethnicity.** The length of each colored bar is proportional to the number of patients  
259 enrolled in the US EAP within the identified age group (years) and race or ethnicity  
260 category. The patient enrollment values are presented relative to analogous categorical  
261 data retrieved from the US Census Bureau.

### 262 Temporal Trends in Enrollment

263 Enrollment in the EAP for convalescent plasma per US state on each day of the EAP is  
264 displayed in **Figure 4**. The individual state and regional aggregates show clear trends of  
265 when COVID-19 was surging during EAP enrollment. **Figure 5** presents enrollment over  
266 time together with the number of active COVID-19 cases per US state. Chronologically,  
267 increases in enrollment in the EAP closely followed the individual state infection rate.  
268 Enrollment in the EAP per 1,000 confirmed COVID-19 cases varied from 0.8 (Vermont)  
269 to 39.1 (Hawaii) patients across US states. The proportion that each US region  
270 contributed to the total enrollment into the EAP varied throughout the program and **Figure**  
271 **6** displays proportional enrollment into the EAP across time by US geographical region,  
272 COVID-19 disease severity, and mechanical ventilation status prior to COVID-19  
273 convalescent plasma transfusion.



274

275

276

277

278


279

280

281

282


**Figure 4. Daily patient enrollment in the US Expanded Access Program (EAP).** Each circle represents one day in which at least one patient was enrolled, within the indicated US state or region. Blue circles represent daily US state enrollments and yellow circles represent daily US region enrollments. Larger circles represent a greater number of daily enrollments within the indicated US state or region. Nil patient enrollments on a given day are not represented with a symbol. States are ordered alphabetically by US region, and an aggregate for each region is also represented.



283

284 **Figure 5. Daily rates of COVID-19-confirmed infections and patient enrollment in**  
285 **the US Expanded Access Program (EAP).** Chronological line charts represent the daily  
286 number of state-wide COVID-19-confirmed infections and EAP patient enrollment  
287 sequentially arranged in a geofaceted depiction of the US. Daily rates are presented as  
288 a moving average across seven days, scaled between 0 (least cases/enrollments) and 1  
289 (most cases/enrollments) for any day in each state. Vertical, dashed grey lines represent  
290 the start date of the EAP (April 3rd, 2020). Values in the lower left corner of each panel  
291 indicate the scaling factor between the two plots (cases/enrollments), which approximates  
292 the number of COVID-19 cases that contributed to one enrollment in the EAP. EAP  
293 enrollment data are not presented for Vermont or Wyoming because total enrollments  
294 were not greater than 10 patients.

295



296

297 **Figure 6. Daily patient enrollment in the US Expanded Access Program (EAP)**  
298 **relative to each US geographical region.** Stacked area chart displaying daily rates of  
299 patient enrollment in the EAP as a proportion of the sum total daily enrollment within each  
300 of four US geographical regions, two categories of COVID-19 disease severity (severe or  
301 life-threatening), and dichotomous representation of mechanical ventilation status prior to  
302 COVID-19 convalescent plasma transfusion. Only patients that received a COVID-19  
303 convalescent plasma transfusion are included in the rightmost panel dichotomized by  
304 mechanical ventilation status.

## 305 Discussion

### 306 Principal findings

307 The US EAP successfully provided access to COVID-19 convalescent plasma to over  
308 105,000 patients, of which nearly 95,000 patients were transfused with convalescent  
309 plasma over the course of five months. Access to convalescent plasma closely kept pace  
310 with increases in confirmed US COVID-19 infections per state over time and there was  
311 substantial inclusion of vulnerable racial and ethnic minority populations. Geographically,  
312 enrollment in the EAP occurred in all US States, the District of Columbia, and the US  
313 territories of Puerto Rico, and the U.S. Virgin Islands. Patients were enrolled from all but  
314 five of US national hospital referral regions, and substantial enrollment occurred in both  
315 metropolitan and non-metropolitan areas.

## 316 **Demographic characteristics of patients enrolled in the EAP**

317 Demographic characteristics of the complete enrolled EAP cohort showed substantial  
318 enrollment among patients over the age of 60 (57.8%), male patients (58.4%), patients of  
319 African American or Black race (18.2%), and patients of Hispanic or Latino ethnicity  
320 (37.2%). African American or Black race and Hispanic or Latino ethnicity make up 13.4%  
321 and 18.5% of the US population, respectively [27]. Previous studies have found that older  
322 [34, 35], male [35], African American or Black race [34, 36, 37], and Hispanic or Latino  
323 [37] individuals are at higher risk of hospitalization for severe or life-threatening COVID-  
324 19. The presented enrollment results from the EAP highlight that this program was able  
325 to provide access to COVID-19 convalescent plasma to demographic groups that have  
326 suffered the largest disease burden from the US COVID-19 epidemic.

## 327 **Chronological and Geographical characteristics**

328 Peak enrollment in the EAP per day closely tracked the number of cases reported by  
329 state as the COVID-19 epidemic developed. Enrollment during April and May, 2020 was  
330 high in Northeastern states, whereas in July and August enrollment peaked in the  
331 Southeast and Southwest regions of mainland US, in line with the development of  
332 'hotspots' in these regions over time [38]. An increase in enrollment in Midwestern states  
333 was observed during August 2020, and this trend was also closely associated with an  
334 increase in confirmed COVID-19 cases in that region. Although there was widespread  
335 participation across US states and territories, there were less than 10 patients enrolled in  
336 both Vermont ( $n = 1$ ) and Wyoming ( $n=9$ ), representing a small fraction of the total  
337 COVID-19 cases in those states. Given that there were no registered clinical trials  
338 involving COVID-19 convalescent plasma in these two states during the time of the EAP,

339 there may have been regulatory or administrative barriers to participation in trials involving  
340 experimental therapeutics for COVID-19.

### 341 **Implications for future pandemics**

342 The success of the EAP in providing rapid access to convalescent plasma in metropolitan  
343 and regional areas of the US that might not otherwise have had access to therapy  
344 provides a framework for future efforts when broad access to a treatment is needed in  
345 response to an infectious disease outbreak. In this regard it is noteworthy that given that  
346 clinical trials were limited to only a few institutions, that most patients treated with plasma  
347 would have had no access without the EAP or single-patient eINDs. The high use of  
348 convalescent plasma within the EAP indicates a high level of acceptance for this therapy  
349 by patients and frontline physicians despite the absence of high-quality data for its clinical  
350 efficacy. The EAP design was particularly effective in providing access to a potentially  
351 effective treatment in minority demographic groups and rural areas that are often  
352 underrepresented in US randomized controlled trials [39, 40].

### 353 **Methodological considerations**

354 The US EAP for COVID-19 convalescent plasma aimed to provide access to a treatment  
355 possibly providing benefit, while randomized clinical trials were in various stages of  
356 development and enrollment. This enrollment report focused on the primary aim of the  
357 EAP of providing access to COVID-19 convalescent plasma; whereas, analyses on  
358 potential efficacy from EAP data have been presented elsewhere [19, 41].

### 359 **Limitations**



360 Numerous challenges were encountered during the development and implementation of  
361 this national registry. Given the constraints on health care resources during the COVID-19  
362 pandemic [42], this national registry used a modern design with creative solutions to  
363 overcome the epidemiological and contextual challenges of the pandemic [43]. These  
364 creative solutions included a central academic IRB for oversight, streamlined registration  
365 for sites and physicians, simple online data collection forms, robust support center  
366 accessible via email or telephone, limited patient exclusion criteria, limited restrictions on  
367 concomitant therapies, and no initiation or monitoring site visits. Several important  
368 limitations resulted from this design, however, including adjustments in required data  
369 collection elements which were inversely related to the number of cases of COVID-19 in  
370 the US, unavailable data due to abridged data collection forms, and missing data due to  
371 the nature of a national registry. Additionally, the EAP was designed to provide access to  
372 convalescent plasma at hospitals and acute care facilities that were not already part of a  
373 clinical trial or did not have the infrastructure to support complex clinical trials. This registry  
374 also did not require training of the local investigators or study team members. The design  
375 of this national registry provided widespread access to convalescent plasma and easy to  
376 complete data collection forms during a worldwide pandemic. This pragmatic approach  
377 did not ensure the highest quality of data nor completeness of data.

## 378 **Conclusions**

379 The EAP provided rapid and broad access to convalescent plasma throughout the US  
380 and some US territories and was effective at providing therapy for demographic groups  
381 that were severely affected by COVID-19. Over time, the EAP provided access to  
382 convalescent plasma in response to sudden and exponential changes in SARS-CoV-2



383 infection rates. Data gathered from the EAP established the COVID-19 convalescent  
384 plasma was generally safe [20, 21] and provided key efficacy data that were an important  
385 component of the scientific evidence considered by the US FDA in the decision to issue  
386 an EUA [19] for convalescent plasma in the treatment of hospitalized adults with COVID-  
387 19. Hence, this program established that it is possible to obtain relevant and actionable  
388 safety and efficacy data during pandemic conditions. The efficient study design of the  
389 EAP may serve as an example for future efforts when broad access to a treatment is  
390 needed in response to a rapidly developing infectious disease providing access in areas  
391 typically underrepresented in clinical studies and thereby allowing capture of  
392 demographic groups that are often poorly represented in clinical trials.

### 393 **Article Information**

394 **Disclaimer:** The views and opinions expressed in this manuscript are those of the  
395 authors and do not reflect the official policy or position of the US Department of Health  
396 and Human Services and its agencies including the Biomedical Research and  
397 Development Authority and the Food and Drug Administration, as well as any agency of  
398 the U.S. government. Assumptions made within and interpretations from the analysis are  
399 not reflective of the position of any US government entity.

400 **Author Contributions:** Drs. Joyner and Carter had full access to all the data in the study  
401 and take responsibility for the integrity of the data and the accuracy of the data analysis.

402 **Conflict of Interest Disclosures:** United Health Group, Millennium Pharmaceuticals,  
403 and Octapharma USA Inc., supported this project. No other disclosures were reported.

404 **Funding/Support:** This project has been funded in part with Federal funds from the  
405 Department of Health and Human Services; Office of the Assistant Secretary for  
406 Preparedness and Response; Biomedical Advanced Research and Development  
407 Authority under Contract No. 75A50120C00096. Additionally, this study was supported in  
408 part by National Center for Advancing Translational Sciences (NCATS) grant  
409 UL1TR002377, National Heart, Lung, and Blood Institute (NHLBI) grant 5R35HL139854  
410 (to MJJ) and grant 1F32HL154320 (to JWS), Natural Sciences and Engineering Research  
411 Council of Canada (NSERC) PDF-532926-2019 (to SAK), National Institute of Diabetes  
412 and Digestive and Kidney Diseases (NIDDK) 5T32DK07352 (to CCW), National Institute  
413 of Allergy and Infectious Disease (NIAID) grants R21 AI145356, R21 AI152318 and R21  
414 AI154927 (to DF), R01 AI152078 9 (to AC), National Heart Lung and Blood Institute RO1  
415 HL059842 (to AC), National Institute on Aging (NIA) U54AG044170 (to SEB), Schwab  
416 Charitable Fund (Eric E Schmidt, Wendy Schmidt donors), United Health Group, National  
417 Basketball Association (NBA), Millennium Pharmaceuticals, Octapharma USA, Inc, and  
418 the Mayo Clinic.

419 **Data Access Statement:** Individual participant data underlying the results reported in  
420 this publication, along with a data dictionary, will be made available to approved  
421 investigators for secondary analyses following the completion of the objectives of the  
422 United States Expanded Access Program to COVID-19 convalescent plasma. Limited  
423 and de-identified data sets will be deposited into a research data repository and may be  
424 shared with investigators under controlled access procedures as approved by the Mayo  
425 Clinic Institutional Review Board. A scientific committee will review requests for the  
426 conduct of protocols approved or determined to be exempt by an Institutional Review

- 427 Board. Requestors will be required to sign a data use agreement. Data sharing must be
- 428 compliant with all applicable Mayo Clinic policies.

## 429 **References**

- 430 1. The L. COVID-19 in the USA: a question of time. *Lancet* (London, England).  
431 2020;395(10232):1229. Epub 2020/04/20. doi: 10.1016/s0140-6736(20)30863-1.  
432 PubMed PMID: 32305080; PubMed Central PMCID: PMC7162627.
- 433 2. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A  
434 Narrative Review. *Ann Intern Med*. 2020;173(5):362-7. Epub 2020/06/04. doi:  
435 10.7326/M20-3012. PubMed PMID: 32491919; PubMed Central PMCID:  
436 PMC7281624.
- 437 3. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW,  
438 et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients  
439 Hospitalized With COVID-19 in the New York City Area. *JAMA*. 2020. Epub 2020/04/23.  
440 doi: 10.1001/jama.2020.6775. PubMed PMID: 32320003; PubMed Central PMCID:  
441 PMC7177629.
- 442 4. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors  
443 Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US.  
444 *JAMA Intern Med*. 2020. Epub 2020/07/16. doi: 10.1001/jamainternmed.2020.3596.  
445 PubMed PMID: 32667668; PubMed Central PMCID: PMC7364338.
- 446 5. Fan E, Beitler JR, Brochard L, Calfee CS, Ferguson ND, Slutsky AS, et al. COVID-  
447 19-associated acute respiratory distress syndrome: is a different approach to  
448 management warranted? *Lancet Respir Med*. 2020;8(8):816-21. Epub 2020/07/10. doi:

449 10.1016/S2213-2600(20)30304-0. PubMed PMID: 32645311; PubMed Central PMCID:  
450 PMCPMC7338016.

451 6. Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al.  
452 Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy. medRxiv.  
453 2020:2020.07.29.20162917. Epub 2020/11/04. doi: 10.1101/2020.07.29.20162917.  
454 PubMed PMID: 33140056; PubMed Central PMCID: PMCPMC7605561.

455 7. Ripoll Sanz J, van Helmond N, Senefeld JW, Wiggins CC, Klassen SA, Baker SE,  
456 et al. Convalescent Plasma for Infectious Diseases: Historical Framework and Use in  
457 COVID-19. *Clinical Microbiology Newsletter*. 2021;ahead of print.

458 8. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark  
459 back: passive immunotherapy for influenza and other serious infections. *Crit Care Med*.  
460 2010;38(4 Suppl):e66-73. Epub 2010/02/16. doi: 10.1097/CCM.0b013e3181d44c1e.  
461 PubMed PMID: 20154602.

462 9. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and  
463 development of passive antibody therapy. *Antimicrob Agents Chemother*.  
464 1994;38(8):1695-702. Epub 1994/08/01. doi: 10.1128/aac.38.8.1695. PubMed PMID:  
465 7985997; PubMed Central PMCID: PMCPMC284624.

466 10. Casadevall A, Scharff MD. Return to the past: the case for antibody-based  
467 therapies in infectious diseases. *Clin Infect Dis*. 1995;21(1):150-61. Epub 1995/07/01.

468 doi: 10.1093/clinids/21.1.150. PubMed PMID: 7578724; PubMed Central PMCID:  
469 PMCPMC7197598.

470 11. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent  
471 plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis*.  
472 2005;24(1):44-6. Epub 2004/12/24. doi: 10.1007/s10096-004-1271-9. PubMed PMID:  
473 15616839; PubMed Central PMCID: PMCPMC7088355.

474 12. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill  
475 Patients With COVID-19 With Convalescent Plasma. *Jama*. 2020;323(16):1582-9. doi:  
476 10.1001/jama.2020.4783.

477 13. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent  
478 Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-  
479 threatening COVID-19: A Randomized Clinical Trial. *Jama*. 2020;324(5):460-70. Epub  
480 2020/06/04. doi: 10.1001/jama.2020.10044. PubMed PMID: 32492084; PubMed Central  
481 PMCID: PMCPMC7270883 COVID-19 testing. Dr Wu reports consulting for Verax  
482 Medical and Grifols, receiving royalties from UptoDate and AABB, and being a volunteer  
483 visiting professor and receiving travel support for giving medical education from the  
484 Chinese Institute of Blood Transfusion. No other disclosures were reported.

485 14. Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, et al.  
486 Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma.

487 Am J Pathol. 2020;190(8):1680-90. Epub 2020/05/31. doi: 10.1016/j.ajpath.2020.05.014.

488 PubMed PMID: 32473109; PubMed Central PMCID: PMC7251400.

489 15. Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al.

490 Convalescent plasma treatment of severe COVID-19: a propensity score-matched control

491 study. Nat Med. 2020;26(11):1708-13. Epub 2020/09/17. doi: 10.1038/s41591-020-1088-

492 9. PubMed PMID: 32934372.

493 16. Egede LE, Walker RJ. Structural Racism, Social Risk Factors, and Covid-19 - A

494 Dangerous Convergence for Black Americans. N Engl J Med. 2020;383(12):e77. Epub

495 2020/07/25. doi: 10.1056/NEJMp2023616. PubMed PMID: 32706952; PubMed Central

496 PMCID: PMC7747672.

497 17. Evans MK. Covid's Color Line - Infectious Disease, Inequity, and Racial Justice. N

498 Engl J Med. 2020;383(5):408-10. Epub 2020/07/30. doi: 10.1056/NEJMp2019445.

499 PubMed PMID: 32726526.

500 18. Joyner MJ. Expanded Access to Convalescent Plasma for the Treatment of

501 Patients with COVID-19. Rochester, MN, US.2020 [updated 08/03/2020; cited 2020

502 10/23/2020]. 1.0:[Available from: <https://www.uscovidplasma.org/physicians-protocol>].

503 19. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al.

504 Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. New

505 England Journal of Medicine. 2021. doi: 10.1056/NEJMoa2031893.

- 506 20. Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al.  
507 Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo  
508 Clin Proc. 2020;95(9):1888-97. Epub 2020/08/31. doi: 10.1016/j.mayocp.2020.06.028.  
509 PubMed PMID: 32861333; PubMed Central PMCID: PMC7368917.
- 510 21. Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al.  
511 Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest.  
512 2020;130(9):4791-7. Epub 2020/06/12. doi: 10.1172/JCI1140200. PubMed PMID:  
513 32525844; PubMed Central PMCID: PMC7456238.
- 514 22. Mayo Clinic. USCovidPlasma. Rochester, MN, US.2020 [cited 2020 10/23/2020].  
515 Available from: <https://www.uscovidplasma.org/>.
- 516 23. US Food and Drug Administration. Code of Federal Regulations Title 21 - Part 50  
517 Section 50.23. 2019.
- 518 24. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap  
519 consortium: Building an international community of software platform partners. J Biomed  
520 Inform. 2019;95:103208. Epub 2019/05/13. doi: 10.1016/j.jbi.2019.103208. PubMed  
521 PMID: 31078660; PubMed Central PMCID: PMC7254481.
- 522 25. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research  
523 electronic data capture (REDCap)--a metadata-driven methodology and workflow  
524 process for providing translational research informatics support. J Biomed Inform.



525 2009;42(2):377-81. Epub 2008/10/22. doi: 10.1016/j.jbi.2008.08.010. PubMed PMID:  
526 18929686; PubMed Central PMCID: PMCPMC2700030.

527 26. OFFICE OF MANAGEMENT AND BUDGET. Revisions to the Standards for the  
528 Classification of Federal Data on Race and Ethnicity. Federal Register; 1997. p. 58782.

529 27. U.S. Census Bureau. Population Estimates 2018. Available from:  
530 <https://www2.census.gov/programs-surveys/popest/datasets/2010-2018/counties/asrh/>.

531 28. The New York Times. Coronavirus US Cases New York City: The New York Times  
532 Company; 2020. Available from:  
533 <https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html>.

534 29. Office of Management and Budget. Standards for Delineating Metropolitan  
535 and Micropolitan Statistical Areas; Notice Federal Register; 2010. p. 37249-52.

536 30. O'Connor SP. United States Regions Washington DC: National Geographic  
537 Society 2012 [01/14/2021]. Available from:  
538 <https://www.nationalgeographic.org/maps/united-states-regions/>.

539 31. American Hospital Directory. Hospital Profiles 2020 [01/14/2021]. Available from:  
540 <https://www.ahd.com/search.php>.

541 32. CMS. Provider of Services Baltimore: Centers for Medicare & Medicaid Services;  
542 2020. Available from: [https://www.cms.gov/Research-Statistics-Data-and-](https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Provider-of-Services)  
543 [Systems/Downloadable-Public-Use-Files/Provider-of-Services](https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Provider-of-Services).

544 33. Hilton DM. Letter of authorization Silver Spring: US Food & Drug Administration;  
545 2020 [01/14/2021].

546 34. Gold JAW, Wong KK, Szablewski CM, Patel PR, Rossow J, da Silva J, et al.  
547 Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 -  
548 Georgia, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(18):545-50. Epub  
549 2020/05/08. doi: 10.15585/mmwr.mm6918e1. PubMed PMID: 32379729; PubMed  
550 Central PMCID: PMC7737948 Journal Editors form for disclosure of potential  
551 conflicts of interest. James M. Blum reports personal fees from Clew Medical, outside the  
552 submitted work. No other potential conflicts of interest were disclosed.

553 35. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of Hospitalized Adults  
554 With COVID-19 in an Integrated Health Care System in California. Jama.  
555 2020;323(21):2195-8. Epub 2020/04/25. doi: 10.1001/jama.2020.7202. PubMed PMID:  
556 32329797; PubMed Central PMCID: PMC7182961 National Institutes of Health  
557 (R35GM128672) during the conduct of the study. No other disclosures were reported.

558 36. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality  
559 among Black Patients and White Patients with Covid-19. The New England journal of

560 medicine. 2020;382(26):2534-43. Epub 2020/05/28. doi: 10.1056/NEJMsa2011686.  
561 PubMed PMID: 32459916; PubMed Central PMCID: PMC7269015.

562 37. Karaca-Mandic P, Georgiou A, Sen S. Assessment of COVID-19 Hospitalizations  
563 by Race/Ethnicity in 12 States. *JAMA Intern Med.* 2021;181(1):131-4. Epub 2020/08/18.  
564 doi: 10.1001/jamainternmed.2020.3857. PubMed PMID: 32804192; PubMed Central  
565 PMCID: PMC7432276 the University of Minnesota, Office of Academic Clinical  
566 Affairs and grants from United Health Foundation during the conduct of the study;  
567 personal fees from Tactile Medical, Precision Health Economics, and Sempre Health; and  
568 grants from the Agency for Healthcare Research and Quality, American Cancer Society,  
569 National Institute for Health Care Management, National Institute on Drug Abuse, and  
570 National Institutes of Health outside the submitted work. Dr Georgiou reported receiving  
571 personal fees from HealthGrades outside the submitted work. No other disclosures were  
572 reported.

573 38. Oster AM, Kang GJ, Cha AE, Beresovsky V, Rose CE, Rainisch G, et al. Trends  
574 in Number and Distribution of COVID-19 Hotspot Counties - United States, March 8-July  
575 15, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(33):1127-32. Epub 2020/08/21. doi:  
576 10.15585/mmwr.mm6933e2. PubMed PMID: 32817606; PubMed Central PMCID:  
577 PMC7439980.

578 39. Evelyn B, Toigo T, Banks D, Pohl D, Gray K, Robins B, et al. Participation of  
579 racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular

580 entities approved 1995-1999. J Natl Med Assoc. 2001;93(12 Suppl):18s-24s. Epub  
581 2002/01/19. PubMed PMID: 11798060; PubMed Central PMCID: PMCPMC2719997.

582 40. Seidler EM, Keshaviah A, Brown C, Wood E, Granick L, Kimball AB. Geographic  
583 distribution of clinical trials may lead to inequities in access. Clin Invest. 2014;4(4):373-  
584 80.

585 41. Administration UFaD. CLINICAL MEMORANDUM - COVID-19 Convalescent  
586 Plasma Silver Spring2020. Available from: <https://www.fda.gov/media/141480/download>.

587 42. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al.  
588 Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med.  
589 2020;383(19):1813-26. Epub 2020/05/24. doi: 10.1056/NEJMoa2007764. PubMed  
590 PMID: 32445440; PubMed Central PMCID: PMCPMC7262788.

591 43. Rojek AM, Horby PW. Modernising epidemic science: enabling patient-centred  
592 research during epidemics. BMC Med. 2016;14(1):212. Epub 2016/12/19. doi:  
593 10.1186/s12916-016-0760-x. PubMed PMID: 27989237; PubMed Central PMCID:  
594 PMCPMC5165716.

595

596

597 **Supplemental Table 1.** Characteristics of acute care facilities and hospitals that enrolled patients  
598 with COVID-19 in the US Expanded Access Program to convalescent plasma.

<b>Site Overview</b>	
	<b>Overall</b>
<b>Part of a Health System</b>	1,803/2,194 (82.2)
<b>Micro/Metropolitan</b>	
Metropolitan	1,918/2,232 (85.9)
Micropolitan	244/2,232 (10.9)
None	70/2,232 (3.1)
<b>Urban/Rural Classification</b>	1,494/2,100 (71.1)
<b>Sole Community Hospital</b>	199/2,194 (9.1)
<b>Rural Referral Center</b>	351/2,194 (16.0)
<b>Teaching Hospital</b>	1,024/2,061 (49.7)
<b>Major Teaching Hospital (member of COTH)</b>	447/2,061 (21.7)
<b>University Affiliated</b>	1,062/2,194 (48.4)

599

600

601 **Supplemental Table 2.** Pre-existing conditions and cardiovascular and lung disease history of  
 602 patients with COVID-19 who enrolled in the US Expanded Access Program to convalescent  
 603 plasma.

<b>Pre-Existing Conditions</b>	
	<b>Overall</b>
<b>Pre-Existing Conditions</b>	
History of lung disease (ex. COPD, lung cancer)	7,225/44,081 (16.4)
Cancer other than above	2,068/44,081 (4.7)
History of cardiovascular conditions	21,673/44,081 (49.2)
Obesity	14,608/44,081 (33.1)
HIV positive	351/44,081 (0.8)
HCV positive (Hepatitis C)	375/44,081 (0.9)
On immunosuppressive therapy	1,631/44,081 (3.7)
Diabetes	17,612/44,081 (40.0)
<b>History of Cardiovascular Disease</b>	
Stroke	1,493/19,490 (7.7)
Coronary Artery Disease (including prior myocardial infarct or MI)	4,019/19,490 (20.6)
Valvular Heart Disease	501/19,490 (2.6)
Peripheral Vascular Disease	702/19,490 (3.6)
Hypertension	16,894/19,490 (86.7)
Arrhythmias	2,199/19,490 (11.3)
Heart Failure	2,413/19,490 (12.4)
Myocarditis	15/19,490 (0.1)
Cardiomyopathy	586/19,490 (3.0)
Prior Coronary Artery Bypass Graft (CABG)	688/19,490 (3.5)
Other	1,959/19,490 (10.1)
None	130/19,490 (0.7)
<b>History of Lung Disease</b>	
COPD (chronic bronchitis, emphysema)	2,403/21,193 (11.3)
Lung cancer	160/21,193 (0.8)
Asthma	1,301/21,193 (6.1)
None	112/21,193 (0.5)
Other lung-related conditions	744/21,193 (3.5)

604

605